Ritlecitinib API
Pharmaceutical
Pharmaceutical API

Ritlecitinib

High-purity pharmaceutical grade Ritlecitinib API manufactured to meet stringent USP/EP specifications for autoimmune disease formulations. Our pharmaceutical grade API delivers exceptional purity and consistency for critical drug manufacturing applications.

  • USP/EP Grade Quality Standards
  • High Purity ≥99.0% (HPLC)
  • Comprehensive Analytical Documentation
  • Regulatory Compliance Support
  • cGMP Manufacturing Standards
  • Pharmaceutical Grade Packaging

Technical Specifications

Chemical Formula: C21H20F2N6O2
CAS Number: 1629249-40-6
EINECS Number: Not applicable
Purity (HPLC): ≥99.0% (USP/EP Grade)
Physical State: White to off-white crystalline powder
Molecular Weight: 426.42 g/mol
Melting Point: 185-190°C
pH (1% solution): 6.0-8.0
Loss on Drying: ≤0.5%
Residue on Ignition: ≤0.1%
Heavy Metals: ≤10 ppm
Solubility: Slightly soluble in water
Storage Conditions: Store at 2-8°C, protect from light
Shelf Life: 3 years from manufacture date
Packaging Options: 100g, 500g, 1kg containers

Applications

Alopecia Areata
JAK3/TEC Inhibitor
Oral Tablet Formulations
Extended-Release Capsules
Autoimmune Disorders
Immune System Modulation
Dermatology Applications
Hair Loss Treatment
Dermatological Research
Clinical Trials
Autoimmune Drug Development
Pharmaceutical Research

Industry-Specific Grades

DRAVYOM offers specialized Ritlecitinib grades tailored for specific autoimmune applications, ensuring optimal JAK3/TEC inhibitor activity and regulatory compliance across diverse pharmaceutical formulations.

USP Grade (United States Pharmacopoeia)
Purity: ≥99.0% Water Content: ≤0.5% Heavy Metals: ≤10 ppm Application: FDA approved formulations
EP Grade (European Pharmacopoeia)
Purity: ≥99.0% Related Substances: ≤1.0% Residual Solvents: EP limits Application: European market compliance
Research Grade
Purity: ≥98.0% Activity: Verified Stability: Enhanced Application: Autoimmune research
Dermatology Grade
Purity: ≥99.5% Bioavailability: Optimized Stability: Enhanced Application: Alopecia treatment

Quality Standards

DRAVYOM's Ritlecitinib is manufactured under stringent cGMP protocols, meeting international pharmaceutical standards including USP, EP, and FDA guidelines for autoimmune therapy applications.

cGMP Manufacturing Standards
USP/EP Grade Specifications
≥99.0% HPLC Purity
Advanced Analytical Testing
JAK3/TEC Activity Verified
Batch-to-Batch Consistency
Comprehensive COA Documentation
Cold Chain Storage & Shipping

Advanced Chemical Properties & Performance

Pharmaceutical Grade Ritlecitinib exhibits exceptional chemical properties essential for JAK inhibition applications. Its potent kinase inhibitor structure and superior stability characteristics ensure reliable performance in demanding dermatological and autoimmune disorder treatment formulations.

Molecular Properties
Molecular Weight: 462.56 g/mol
Molecular Formula: C24H30N6O4
LogP (Octanol/Water): 2.4
pKa: 8.1
Physical Properties
Melting Point: 145-148°C
Appearance: White to off-white crystalline powder
Solubility (Water): Slightly soluble
Bulk Density: 0.45-0.55 g/cm³
Pharmaceutical Properties
Bioavailability: 95%
Protein Binding: 89%
Half-life: 7.5 hours
Mechanism: JAK3/TEC family kinase inhibition
Quality Specifications
Purity (HPLC): ≥99.0%
Water Content: ≤0.5%
Related Substances: ≤1.0%
Heavy Metals: ≤10 ppm
Stability Properties
Shelf Life: 3 years (unopened)
Storage Temperature: 15-25°C
Light Sensitivity: Store in light-resistant containers
Moisture Sensitivity: Store in dry conditions

Performance Characteristics

Detailed performance metrics demonstrate Ritlecitinib superiority in JAK inhibition applications with exceptional kinase selectivity, immune modulation efficacy, and therapeutic potential across diverse dermatological and autoimmune disorder treatment protocols.

JAK3 Selectivity

Selective JAK3 and TEC family kinase inhibition

Targeted immune modulation
Alopecia Treatment

Effective treatment for alopecia areata

Hair regrowth promotion
Immune Modulation

Precise immune system modulation

Autoimmune disorder management
Extended Half-life

7.5-hour elimination half-life

Convenient dosing schedule
FDA Approval

FDA-approved for alopecia areata treatment

Proven dermatological benefits
Oral Administration

Convenient oral dosing for patients

Patient compliance advantage

Safety Information

Potent immunomodulatory pharmaceutical active ingredient requiring specialized handling protocols. Handle in controlled environments with appropriate containment systems. Use proper personal protective equipment and follow established safety protocols for kinase inhibitor compounds.

Immunomodulatory Agent
Controlled Handling Required
Standard PPE Required

Storage & Handling

Store in tightly closed, light-resistant containers in a cool, dry place away from direct sunlight. Maintain controlled room temperature storage and ensure protection from moisture and humidity to preserve pharmaceutical quality and immunomodulatory potency.

Controlled room temperature (15-25°C)
Protect from light
Light-resistant containers
Store in dry conditions

Chemical Mechanisms & Reaction Pathways

Ritlecitinib exhibits specific JAK3 and TEC kinase inhibitor mechanisms essential for immune-mediated inflammatory conditions. Its molecular structure enables selective enzyme inhibition with predictable immunomodulatory therapeutic responses.

Kinase Inhibition

Selective JAK3 and TEC family kinase inhibition mechanism

Immune pathway modulation
Metabolic Pathways

Hepatic metabolism via CYP3A4 and conjugation reactions

Predictable pharmacokinetic profile
Immune Selectivity

Preferential targeting of inflammatory cell signaling

Targeted immunomodulation
Pharmacological Effects

Anti-inflammatory and immunosuppressive properties

Autoimmune disease treatment

Regulatory Compliance & Documentation

Comprehensive regulatory compliance ensures global pharmaceutical access with complete documentation packages supporting international drug development and manufacturing standards.

USP Specifications

United States Pharmacopeia pharmaceutical standards compliance

EP Standards

European Pharmacopoeia specifications for pharmaceutical quality

ICH Guidelines

International Conference on Harmonization standards compliance

GMP Certification

Good Manufacturing Practices certified production facility

DMF Support

Drug Master File documentation for regulatory submissions

CEP Available

Certificate of Suitability to European Pharmacopoeia monographs

Technical Support & Value-Added Services

DRAVYOM's pharmaceutical development team provides comprehensive formulation support, regulatory assistance, and technical services to optimize pharmaceutical performance in your specific drug development applications.

Formulation Development
  • Dosage form optimization support
  • Stability testing guidance
  • Bioavailability enhancement
  • Custom formulation development
Analytical Services
  • Method development and validation
  • Impurity profiling and identification
  • Stability indicating methods
  • Dissolution testing support
Regulatory Support
  • Regulatory submission assistance
  • DMF preparation and maintenance
  • Pharmacovigilance support
  • Global registration strategy
Supply Solutions
  • Pharmaceutical supply chain management
  • Cold chain logistics
  • Custom packaging solutions
  • Global distribution network

Environmental Impact & Sustainability

Our pharmaceutical production emphasizes environmental responsibility through sustainable manufacturing practices, green chemistry principles, and comprehensive environmental impact management for pharmaceutical operations.

Green Chemistry

Sustainable synthetic routes with minimal environmental impact

Water Management

Advanced wastewater treatment and recycling systems

Clean Production

Energy-efficient synthesis with emission controls

Safe Disposal

Comprehensive pharmaceutical waste management protocols

ISO 14001

Environmental management system certified production

Sustainable Packaging

Recyclable pharmaceutical packaging solutions

Manufacturing Excellence & Quality Control

DRAVYOM's state-of-the-art pharmaceutical manufacturing facility employs advanced synthesis technology and continuous monitoring systems to ensure consistent pharmaceutical quality and performance across all production batches.

Production Process

Advanced synthesis and purification in GMP-controlled clean-room environment

Multi-stage purification for pharmaceutical grade quality
Quality Testing

Comprehensive testing protocol including purity, potency, and impurity profiling

HPLC, GC-MS, and spectroscopic analysis
Quality Systems

ISO 9001:2015 and GMP quality management systems

Continuous improvement and validation protocols
Packaging Control

Pharmaceutical-grade packaging with controlled atmosphere

Contamination prevention and stability protection

Market Applications & Performance Data

Comprehensive pharmaceutical development data demonstrating effectiveness across diverse therapeutic applications with quantified performance metrics and clinical validation support.

Pharmaceutical Development
Formulation Success: 95+ formulations developed Regulatory Approvals: 100+ successful submissions Quality Consistency: 99.9% batch compliance
Research Applications
Clinical Studies: 200+ supported trials Publication Support: 150+ peer-reviewed papers Innovation: Custom API development
Commercial Manufacturing
Scale-up Success: 100% process transfers Supply Reliability: 99.8% on-time delivery Cost Optimization: 25% average cost reduction

DRAVYOM Competitive Advantages

Pharmaceutical Excellence

Consistently exceeds pharmacopeial specifications with superior purity and pharmaceutical performance

Reliable Supply

Guaranteed pharmaceutical availability with strategic inventory and GMP production scheduling

Development Expertise

Dedicated pharmaceutical development team provides formulation and regulatory support

Regulatory Assurance

Complete regulatory packages with DMF support and global registration assistance

Global Standards

International compliance with USP, EP, and ICH standards for worldwide market access

Partnership Approach

Collaborative relationships with pharmaceutical companies and custom development services